Paul B. Manning

Paul B. Manning, listed as board member, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Taysha Gene Therapies, Inc., Liquidia Corp and Candel Therapeutics, Inc. In total, 30 filings cover trades dated from 14 May 2021 to 23 February 2026.

In open-market terms, that means 20 purchases worth €50.2M on one side and 1 sale worth €3.7M on the other. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 4 share grants. Since January 2026: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €1.8M. On 6 out of 20 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 26 February 2026, reports an open-market purchase of €2.5M in Candel Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.